US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Palvella Therapeutics

25.40

+1.918.13%

Post-market: 25.400.00000.00%17:24 EDT

Volume:48.49K

Turnover:1.21M

Market Cap:280.81M

PE:-5.03

High:25.88

Open:24.10

Low:23.52

Close:23.49

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Palvella Therapeutics Inc. Files Initial Statement of Beneficial Ownership for Chief Commercial Officer Ashley Kline

Palvella Therapeutics Advances in Rare Skin Disease Therapies

Palvella Therapeutics Strengthens Executive Leadership Team With Appointment of Rare Disease Commercial Veteran Ashley Kline as Chief Commercial Officer

THOMSON REUTERS

Press Release: Palvella Therapeutics Strengthens Executive Leadership Team with Appointment of Rare Disease Commercial Veteran Ashley Kline as Chief Commercial Officer

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/PVLA"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PVLA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PVLA\",,,,,undefined,":{"symbol":"PVLA","market":"US","secType":"STK","nameCN":"Palvella Therapeutics","latestPrice":25.4,"timestamp":1749240000000,"preClose":23.49,"halted":0,"volume":48489,"hourTrading":{"tag":"盘后","latestPrice":25.4,"preClose":25.4,"latestTime":"17:24 EDT","volume":120,"amount":3047.51,"timestamp":1749245066126},"delay":0,"floatShares":5730612,"shares":11055665,"eps":-5.045167,"marketStatus":"Market Closed","change":1.91,"latestTime":"06-06 16:00:00 EDT","open":24.1,"high":25.88,"low":23.52,"amount":1210678.68579,"amplitude":0.100468,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-5.045167,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1749456000000},"marketStatusCode":7,"adr":0,"listingDate":1435636800000,"exchange":"NASDAQ","adjPreClose":23.49,"preHourTrading":{"tag":"盘前","latestPrice":23.49,"preClose":23.49,"latestTime":"08:26 EDT","volume":20,"amount":469.79999999999995,"timestamp":1749212800674},"postHourTrading":{"tag":"盘后","latestPrice":25.4,"preClose":25.4,"latestTime":"17:24 EDT","volume":120,"amount":3047.51,"timestamp":1749245066126},"volumeRatio":0.5341563034301509,"impliedVol":0.4412,"impliedVolPercentile":0.5},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PVLA\",,,,,undefined,":{"symbol":"PVLA","floatShares":5730612,"roa":"-18.39%","roe":"-89.30%","lyrEps":-7.832217,"volumeRatio":0.5341563034301509,"shares":11055665,"dividePrice":0,"high":25.88,"amplitude":0.100468,"preClose":23.49,"low":23.52,"week52Low":6.2,"pbRate":"5.05","week52High":29.27,"institutionHeld":0,"latestPrice":25.4,"eps":-5.045167,"divideRate":0,"volume":48489,"delay":0,"ttmEps":-5.045167,"open":24.1,"prevYearClose":12,"prevWeekClose":24.13,"prevMonthClose":24.13,"prevQuarterClose":27.99,"fiveDayClose":24.13,"twentyDayClose":23.04,"sixtyDayClose":29},"@#url:\"https://hq.skytigris.cn/market/plate/belongs/PVLA\",params:#limit:6,delay:false,,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PVLA\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2540086412","title":"Palvella Therapeutics Inc. Files Initial Statement of Beneficial Ownership for Chief Commercial Officer Ashley Kline","url":"https://stock-news.laohu8.com/highlight/detail?id=2540086412","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540086412?lang=en_us&edition=fundamental","pubTime":"2025-06-04 09:08","pubTimestamp":1748999336,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics Inc. has filed an initial statement of beneficial ownership. The filing identifies Ashley Hartmann Kline as the beneficial owner, serving in the role of Chief Commercial Officer. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Palvella Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 03, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250604:nNDL6H755C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA","BK4139"],"gpt_icon":0},{"id":"2539108202","title":"Palvella Therapeutics Advances in Rare Skin Disease Therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2539108202","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539108202?lang=en_us&edition=fundamental","pubTime":"2025-05-31 11:55","pubTimestamp":1748663732,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics, Inc. ( ($PVLA) ) has released its Q1 earnings. Here is a breakdown of the information Palvella Therapeutics, Inc. presented ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/palvella-therapeutics-advances-in-rare-skin-disease-therapies?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/palvella-therapeutics-advances-in-rare-skin-disease-therapies?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PVLA","BK4139"],"gpt_icon":0},{"id":"2538465753","title":"Palvella Therapeutics Strengthens Executive Leadership Team With Appointment of Rare Disease Commercial Veteran Ashley Kline as Chief Commercial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2538465753","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538465753?lang=en_us&edition=fundamental","pubTime":"2025-05-27 20:00","pubTimestamp":1748347202,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250527:nTUA3DDGCF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PVLA"],"gpt_icon":0},{"id":"2538784465","title":"Press Release: Palvella Therapeutics Strengthens Executive Leadership Team with Appointment of Rare Disease Commercial Veteran Ashley Kline as Chief Commercial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2538784465","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538784465?lang=en_us&edition=fundamental","pubTime":"2025-05-27 20:00","pubTimestamp":1748347200,"startTime":"0","endTime":"0","summary":"Ms. Kline to lead Palvella's commercial buildout for planned standalone U.S. launch of QTORIN 3.9% rapamycin anhydrous gel  for microcystic lymphatic malformations, a serious, rare, and lifelong genetic disease affecting an estimated more than 30,0000 patients in the U.S., if approved. Under Kline's leadership at Dompé, Oxervate, a first-in-disease topical therapy for rare disease neurotrophic keratitis, scaled to over $500 million in annual U.S. sales while achieving early profitability. Earlier in her career, Ms. Kline was a member of the commercial team at Genentech and a consultant for Bain and Company. She also held commercial roles at Santen Pharmaceuticals and Adverum Biotech. Ms. Kline earned her M.B.A. from the Kellogg School of Management at Northwestern University with majors in Finance, Decision Science, and Analytical Consulting and a","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4120","BK4585","TM","PVLA","R","03160","BK4099","BK4555","BK4588","TISI","BK4232","BK4604","BK4022","BK4139"],"gpt_icon":0}],"pageSize":4,"totalPage":20,"pageCount":1,"totalSize":77,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PVLA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-15","symbol":"PVLA","fiscalQuarterEnding":"2025/03","expectedEps":-3.4,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1747281600000,"reportTimeType":"pre","actualEps":-0.74},{"market":"US","date":"2025-03-31","symbol":"PVLA","fiscalQuarterEnding":"2024/12","expectedEps":-0.39,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1743393600000,"reportTimeType":"pre","actualEps":4},{"market":"US","date":"2024-11-13","symbol":"PVLA","fiscalQuarterEnding":"2024/09","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731474000000,"reportTimeType":"post","actualEps":-2.19},{"market":"US","date":"2024-08-14","symbol":"PVLA","fiscalQuarterEnding":"2024/06","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1723608000000,"reportTimeType":"post","actualEps":-2.76},{"market":"US","date":"2024-05-15","symbol":"PVLA","fiscalQuarterEnding":"2024/03","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1715745600000,"reportTimeType":"post","actualEps":-3.95}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PVLA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PVLA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.1111,"buy":0.8889,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.8889,"analysts":9,"updateTime":1744257600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/PVLA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"PVLA","date":"2025-06-06","current":-11.250599,"percent":0.333333,"low":-17.690417,"twenty":-14.245514,"median":19.990339,"eighty":31.090781,"high":46.119317,"avg":11.420347,"sd":22.084191,"marketCap":259697570},"quantilePoints":[{"date":"2024-12-20","current":19.163371,"twenty":19.017062,"median":19.163371,"eighty":20.457893,"marketCap":135216749},{"date":"2024-12-27","current":19.083855,"twenty":18.842127,"median":19.083855,"eighty":19.659551,"marketCap":134655684},{"date":"2025-01-03","current":21.071757,"twenty":18.969352,"median":19.083855,"eighty":19.907642,"marketCap":148682317},{"date":"2025-01-10","current":22.216788,"twenty":19.083855,"median":19.083855,"eighty":21.987782,"marketCap":156761658},{"date":"2025-01-17","current":20.960435,"twenty":19.083855,"median":20.523096,"eighty":21.13537,"marketCap":147896826},{"date":"2025-01-24","current":19.863113,"twenty":19.083855,"median":20.650322,"eighty":21.071757,"marketCap":140154124},{"date":"2025-01-31","current":20.674177,"twenty":19.083855,"median":20.658273,"eighty":21.151273,"marketCap":145876991},{"date":"2025-02-07","current":24.729496,"twenty":19.083855,"median":20.674177,"eighty":22.089563,"marketCap":174491323},{"date":"2025-02-14","current":31.090781,"twenty":19.083855,"median":20.912725,"eighty":23.46519,"marketCap":219376551},{"date":"2025-02-21","current":30.565975,"twenty":19.147468,"median":20.992241,"eighty":24.783567,"marketCap":215673520},{"date":"2025-02-28","current":30.804523,"twenty":19.723165,"median":21.111515,"eighty":29.913943,"marketCap":217356716},{"date":"2025-03-07","current":39.042387,"twenty":20.066674,"median":21.469337,"eighty":30.728188,"marketCap":275483086},{"date":"2025-03-14","current":43.678174,"twenty":20.34657,"median":22.439433,"eighty":31.793703,"marketCap":308193196},{"date":"2025-03-21","current":44.751641,"twenty":20.49288,"median":23.46519,"eighty":33.810231,"marketCap":315767578},{"date":"2025-03-28","current":44.688028,"twenty":20.604203,"median":24.292158,"eighty":40.654974,"marketCap":315318726},{"date":"2025-04-04","current":-15.155991,"twenty":19.723165,"median":23.46519,"eighty":39.236406,"marketCap":264229553},{"date":"2025-04-11","current":-13.752893,"twenty":19.083855,"median":22.439433,"eighty":38.266311,"marketCap":239767934},{"date":"2025-04-17","current":-15.396161,"twenty":19.00752,"median":21.77945,"eighty":36.545583,"marketCap":268416676},{"date":"2025-04-25","current":-16.047148,"twenty":-12.608925,"median":21.151273,"eighty":34.239617,"marketCap":279765986},{"date":"2025-05-02","current":-15.493342,"twenty":-14.192783,"median":21.008144,"eighty":33.36176,"marketCap":270110923},{"date":"2025-05-09","current":-14.42287,"twenty":-14.682214,"median":20.912725,"eighty":33.091405,"marketCap":251448313},{"date":"2025-05-16","current":-10.548775,"twenty":-14.614161,"median":20.674177,"eighty":32.251716,"marketCap":243497378},{"date":"2025-05-23","current":-10.577479,"twenty":-14.552086,"median":20.64237,"eighty":31.796884,"marketCap":244159956},{"date":"2025-05-30","current":-11.868448,"twenty":-14.483678,"median":20.515145,"eighty":31.510626,"marketCap":273959378},{"date":"2025-06-06","current":-11.250599,"twenty":-14.245514,"median":19.990339,"eighty":31.090781,"marketCap":259697570}],"updateTime":1749375407665}}}